Potential remedy reviews for 2023
The CMA is consulting on remedies that it should consider reviewing across its portfolio of market and merger remedies.
We are publishing an Invitation to Comment concerning a number of specific remedies where our initial screening has identified a possible change in circumstances indicating that a review of that remedy may be appropriate.
We also invite comments concerning any of the Competition and Market Authority (CMA)’s other market and merger remedies. which can be found on the CMA’s Markets and monopolies register of orders, undertakings and directions, and its Mergers orders and undertakings register.
The CMA is considering whether to prioritise the launch of reviews of the remedies listed in the invitation to comment document below.
The CMA invites comments from stakeholders on the possible changes of circumstance identified in the Invitation to Comment document, and on whether carrying out a review should be considered to be an administrative priority for the CMA.
The information received will assist the CMA in reaching a decision on whether or not to launch reviews of the remedies and the prioritisation of such launches.
Issues which are not directly relevant to the remedies concerned are outside of the scope of this consultation.
Respondents should provide their views supported with relevant evidence where possible, in writing to the CMA at the address below.
The CMA requests that all submissions be accompanied by a non-confidential version which the respondent would be willing to have published on the CMA website in the event that a formal review is launched.